Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Vasc Surg Venous Lymphat Disord ; 10(2): 417-422, 2022 03.
Article in English | MEDLINE | ID: mdl-34352423

ABSTRACT

PURPOSE: To evaluate the use of inframalleolar access for endovenous ablation when treating advanced venous disease with nonthermal nontumescent (NTNT) techniques. METHODS: This single-center retrospective study included 109 patients with advanced venous disease, treated using inframalleolar access between May 2018 and March 2020. NTNT techniques included ClariVein (Merit Medical Systems, South Jordan, Utah) and ScleroSafe (VVT Medical, Kefar Sava, Israel). Outcomes measured were postprocedure pain, leg edema, ulcer healing and recurrence rates, and venous insufficiency recurrence. RESULTS: Seventy-seven patients (70%) were treated with ClariVein and 32 (30%) with ScleroSafe. Postprocedure pain score (range, 0-10) after 1 week decreased from a preprocedure median of 5 (interquartile range, 3-6) to 1 ((interqartiel range, 0-2) (P = .0001). Complete wound healing was achieved in 38 patients (43.7%) after 30 days and in 71 patients (81.6%) after 90 days. One patient developed an ulcer recurrence and six developed venous insufficiency recurrence. There was no reported nerve or skin injuries. CONCLUSIONS: NTNT ablation techniques using inframalleolar access are effective and safe without risk of nerve damage. Their use facilitates ulcer healing and limits pain in patients with advanced disease.


Subject(s)
Endovascular Procedures , Polidocanol/administration & dosage , Saphenous Vein , Sclerosing Solutions/administration & dosage , Sclerotherapy , Sodium Tetradecyl Sulfate/administration & dosage , Varicose Ulcer/therapy , Venous Insufficiency/therapy , Aged , Endovascular Procedures/adverse effects , Female , Humans , Male , Middle Aged , Polidocanol/adverse effects , Recurrence , Retrospective Studies , Saphenous Vein/diagnostic imaging , Sclerosing Solutions/adverse effects , Sclerotherapy/adverse effects , Sodium Tetradecyl Sulfate/adverse effects , Time Factors , Treatment Outcome , Varicose Ulcer/diagnostic imaging , Venous Insufficiency/diagnostic imaging , Wound Healing
2.
Blood Adv ; 4(24): 6291-6297, 2020 12 22.
Article in English | MEDLINE | ID: mdl-33351124

ABSTRACT

Direct oral anticoagulants (DOACs) are increasingly prescribed in treatment of cancer-associated thrombosis, but limited data exist regarding safety of DOACs in patients with brain metastases. We aimed to determine the incidence of intracranial hemorrhage (ICH) in patients with brain metastases receiving DOACs or low-molecular-weight heparin (LMWH) for venous thromboembolism or atrial fibrillation. An international 2-center retrospective cohort study was designed. Follow-up started on the first day of concomitant anticoagulation and brain tumor diagnosis. At least 2 brain imaging studies were mandated. The primary outcome was the cumulative incidence of any spontaneous ICH at 12-month follow-up with death as a competing risk. Major ICH was defined as spontaneous, ≥10 mL in volume, symptomatic, or requiring surgical intervention. Imaging studies were centrally reviewed by a neuroradiologist blinded for anticoagulant type. PANWARDS (platelets, albumin, no congestive heart failure, warfarin, age, race, diastolic blood pressure, stroke) score for prediction of ICH was calculated. We included 96 patients with brain metastases (41 DOAC, 55 LMWH). The 12-month cumulative incidence of major ICH was 5.1% in DOAC-treated patients and 11.1% in those treated with LMWH (hazard ratio [HR], 0.45; 95% confidence interval [CI], 0.09-2.21). When anticoagulation was analyzed as a time-varying covariate, the risk of any ICH did not differ between DOAC- and LMWH-treated patients (HR, 0.98; 95% CI, 0.28-3.40). PANWARDS score was not associated with ICH risk. This international 2-center study suggests comparable safety of LMWH and DOACs in patients with brain metastases.


Subject(s)
Brain Neoplasms , Heparin, Low-Molecular-Weight , Administration, Oral , Anticoagulants/adverse effects , Humans , Intracranial Hemorrhages/chemically induced , Intracranial Hemorrhages/drug therapy , Intracranial Hemorrhages/epidemiology , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...